They'll Always Be Your Babies.
Make Sure Your Teen Gets a Second Shot to Help Prevent Meningitis.1


What Is Meningococcal Meningitis?

Meningococcal meningitis is a bacterial infection that results in inflammation of the lining of the brain and spinal cord, which can cause severe illness and even death in less than 24 hours.2-4 Teenagers are at increased risk for the disease and can suffer devastating consequences.3,5,6 Of the 800 to 1200 cases of meningococcal disease in the US each year, 10-15% are fatal.5,7-9

In 24 Hours, Meningococcal Meningitis Can Have Devastating Consequences2-4,10

About 1 in 5 people who survive meningococcal meningitis can suffer permanent complications such as3,6,11:

  • Amputation of limbs, fingers, or toes
  • Severe scarring
  • Brain damage
  • Hearing loss
  • Kidney damage

Meningococcal Meningitis Is Contagious

The bacteria that cause meningococcal meningitis can be spread through the exchange of oral secretions (saliva) during common activities; such as2,5,12,13:

  • Kissing
  • Sharing utensils and drinking glasses

Risk factors for meningococcal meningitis include:

  • Living in close quarters (ie, dormitories)
  • Smoking or being exposed to smoke

Protect Your Teen With a Meningitis Booster Shot

Millions of teens are under-protected.14-16 That's why the Centers for Disease Control and Prevention (CDC) recommends a meningitis booster shot at 16 to 18 years of age.1 Even if your teen already received a meningitis shot at age 11 or 12 years, he or she still needs a second vaccination as early as 16 years of age.1

Amy's Story

Amy's Story

"I'd hate for someone to go through what I had to go through."

Watch Now 
Bob and Dee Dee's Story

Bob and Dee Dee's Story

"She started feeling sick on Tuesday, and by Wednesday she was gone."

Watch Now 


References

  1. Centers for Disease Control and Prevention (CDC). Advisory Committee on Immunization Practices (ACIP) recommended immunization schedules for persons aged 0 through 18 years and adults aged 19 years and older—United States, 2013. MMWR. 2013a;62(suppl):1-19.
  2. Apicella MA. Neisseria meningitidis. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 7th ed. Philadelphia, PA: Churchill Livingstone Elsevier;2010;2737-2752.
  3. Erickson LJ, De Wals P, McMahon J, Heim S. Complications of meningococcal disease in college students. Clin Infect Dis. 2001;33(5):737-739.
  4. Thompson MJ, Ninis N, Perera R, et al. Clinical recognition of meningococcal disease in children and adolescents. Lancet. 2006;367(9508):397-403.
  5. Atkinson W, Wolfe S, Hamborsky J, McIntyre L, eds. Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases (The Pink Book). 12th ed. Washington DC: Public Health Foundation; 2011.
  6. Borg J, Christie D, Coen PG, Booy R, Viner RM. Outcomes of meningococcal disease in adolescence: prospective, matched-cohort study. Pediatrics. 2009;123(3):e502-e509.
  7. CDC. Prevention and Control of Meningococcal Disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2013b;62(2):1-32.
  8. CDC. Notifiable diseases and mortality tables [provisional]—week ending December 29, 2012. MMWR. 2013c;61(51 & 52):ND-719-ND-732.
  9. Thigpen MC, Whitney CG, Messonnier NE, et al; Emerging Infections Programs Network. Bacterial meningitis in the United States, 1998-2007. N Engl J Med. 2011;364(21):2016-2025.
  10. Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet. 2007;369(9580):2196-2210.
  11. Erickson L, De Wals P. Complications and sequelae of meningococcal disease in Quebec, Canada, 1990-1994. Clin Infect Dis. 1998;26(5):1159-1164.
  12. Bruce MG, Rosenstein NE, Capparella JM, Shutt KA, Perkins BA, Collins M. Risk factors for meningococcal disease in college students. JAMA. 2001;286(6):688-693.
  13. MacLennan J, Kafatos G, Neal K, et al; United Kingdom Meningococcal Carriage Group. Social behavior and meningococcal carriage in British teenagers. Emerg Infect Dis. 2006;12(6):950-957.
  14. CDC. Updated Recommendations for Use of Meningococcal Conjugate Vaccines — Advisory Committee on Immunization Practices (ACIP), 2010. MMWR. 2011;60(3):72-76.
  15. Sanofi Pasteur Inc. Data on file (2nd dose immunization rates), April 2013. MKT26442
  16. United Stated Census Bureau. Age and Sex Composition: 2010. Washington, DC. U.S. Department of Commerce; 2011.